Patent ID: 7312190

Claim:
The pharmaceutical composition comprising an ApoA-I agonist and a pharmaceutically acceptable carrier, excipient or diluent; wherein the ApoA-I agonist is in the form of an ApoA-I agonist-lipid complex, said complex comprising the ApoA-I agonist and a lipid; wherein the ApoA-I agonist comprises: a 22 to 29-residue peptide or peptide analogue which forms an amphipathic α-helix in the presence of lipids and which comprises formula (I): Z 1 -X 1 -X 2 -X 3 -X 4 -X 5 -X 6 -X 7 -X 8 -X 9 -X 10 -X 11 -X 12 -X 13 -X 14 -X 15 -X 16 -X 17 -X 18 -X 19 X 20 -X 21 -X 22 X 23 Z 2 or a pharmaceutically acceptable salt thereof, wherein: X 1 is Pro (P), Ala (A), Gly (G), Gln (Q), Asn (N), Asp (D) or D-Pro (p); X 2 is an aliphatic residue; X 3 is Leu (L) or Phe (F); X 4 is an acidic residue; X 5 is Leu (L) or Phe (F); X 6 is Leu (L) or Phe (F); X 7 is a hydrophilic residue; X 8 is an acidic or a basic residue; X 9 is Leu (L) or Gly (G); X 10 is Leu (L), Trp (W) or Gly (G); X 11 is a hydrophilic residue; X 12 is a hydrophilic residue; X 13 is Gly (G) or an aliphatic residue; X 14 is Leu (L), Trp (W), Gly (G) or Nal; X 15 is is a hydrophilic residue; X 16 is a hydrophobic residue; X 17 is a hydrophobic residue; X 18 is Gln (Q), Asn (N) or a basic residue; X 19 is Gln (Q), Asn (N) or a basic residue; X 20 is a basic residue; X 21 is an aliphatic residue; X 22 is a basic residue; X 23 is absent or a basic residue; Z 1 is H 2 N— or RC(O)NR′—; Z 2 is —C(O)NRR, —C(O)OR or —C(O)OH or a salt thereof; each R is independently —H, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkenyl, (C 1 -C 6 )alkynyl, (C 5 -C 20 )aryl, (C 6 -C 26 )alkaryl, 5-20 membered heteroaryl, 6-26 membered alkheteroaryl or a 1 to 7-residue peptide or peptide analogue in which one or more bonds between residues 1-7 are independently a substituted amide, an isostere of an amide or an amide mimetic; each R′ is independently —H, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkenyl, (C 1 -C 6 )alkynyl, (C 5 -C 20 )aryl, (C 6 -C 26 )alkaryl, 5-20 membered heteroaryl or 6-26 membered alkheteroaryl; and each “-” between residues X 1 through X 23 independently designates an amide linkage, a substituted amide linkage, an isostere of an amide or an amide mimetic; or a N-terminally blocked form, a C-terminally blocked form, or an N- and C-terminally blocked form of formula (I).